Protocol Ledger

NCT04657991 · Phase III · ACTIVE NOT RECRUITING

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Interventional Phase III clinical trial protocol NCT04657991 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-01-15 Enrollment: 257 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04657991
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)257 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04657991
Protocol FieldVerified Registry Value
NCT IdentifierNCT04657991
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment257 participants (ACTUAL)
Registered Start Date2021-01-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04657991
Hospital Research SiteLocationSite Profile
Massachusetts General HospitalBoston, MAOpen Hospital Dossier ->
University of Cincinnati Medical CenterCincinnati, OHOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI